Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis

Vox Sanguinis

Volumn 111, Issue 4, 2016, Pages 350-356

  Thiele, T ^a   Alt Mayer, T ^b   Greinacher, A ^a   Bux, J ^c  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b German Red Cross Blood Service West   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

apheresis platelets; donor exposure; pooled platelets; transfusion transmitted infection

Indexed keywords

ARTICLE; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; GERMANY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RATE; MAJOR CLINICAL STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS; ADVERSE EFFECTS; BLOOD SAFETY; PHYSIOLOGY; RISK ASSESSMENT; THROMBOCYTE;

BLOOD DONORS; BLOOD PLATELETS; BLOOD SAFETY; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS; RISK ASSESSMENT;

EID: 84992588875     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12433     Document Type: Article

References (35)

1. Vamvakas EC: Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49:2743–2758
2. Peterman TA, Jaffe HW, Feorino PM, et al.: Transfusion-associated acquired immunodeficiency syndrome in the United States. JAMA 1985; 254:2913–2917
3. Bird SM: Recipients of blood or blood products “at vCJD risk”. BMJ 2004; 328:118–119
4. Wilding R, Cotton S, Dobbin J, et al.: Time-based analysis of the apheresis platelet supply chain in England. Vox Sang 2011; 101:247–249
5. Pathogen inactivation of platelets - Report of the SaBTO Working Group. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/324354/SaBTO_platelets_report.pdf, Advisory Committee on the Safety of Blood, Tissues and Organs, 2014 (accessed 21 June 2016)
6. Vamvakas EC, Hitzler WE: Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany. Clin Lab 2013; 59:1–22
7. van Hoeven LR, Janssen MP, Rautmann G: The collection, testing and use of blood and blood components in Europe; in Department of Biological Standardisation ONH, European Directorate for the Quality of Medicines and HealthCare (EDQM), Council of Europe (ed). 2011
8. Slichter SJ: Evidence-based platelet transfusion guidelines. ASH Educ Program Book 2007; 2007:172–178
9. Thiele T, Heddle N, Greinacher A: Donor exposures in recipients of pooled platelet concentrates. N Engl J Med 2013; 368:487–489
10. Thiele T, Heddle N, Greinacher A: Pooled platelet concentrates or apheresis platelets? N Engl J Med 2013; 368:1849
11. an der Heiden M, Ritter S, Hamouda O, et al.: Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany. Vox Sang 2015; 108:123–130
12. Haschberger B, Waterkamp A, Heiden M, et al.: Report on notifications pursuant to Section 21 German transfusion act for 2001 and 2002. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2005; 48:99–119
13. Waterkamp A, Haschberger B, Hesse J, et al.: Report on notifications with respect to section sign 21 German transfusion act for 2003 and 2004. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007; 50:209–229
14. Haschberger B, Henseler O, Hesse J, et al.: Report on notifications pursuant to section 21 German transfusion act for 2005 and 2006. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2008; 51:353–372
15. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to section 21 German transfusion act for 2007. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2009; 52:715–731
16. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to section 21 of the German transfusion act for the years 2008 and 2009. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2010; 53:1089–1103
17. Henseler O, Heiden M, Haschberger B, et al.: Report on notifications pursuant to section sign21 German transfusion act for 2010 and 2011. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013; 56:1352–1367
18. Paul-Ehrlich-Institut: Reports on blood supply in compliance with the German transfusion act §21. [Online: http://www.pei.de/EN/information/blood-supply/reports-blood-supply-tfg21-node.html] (accessed 21 June 2016)
19. Offergeld R, Ritter S, Faensen D, et al.: Report of the Robert Koch Institute according to article 22 of the transfusion act for the years 2001 and 2002. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2004; 47:1216–1229
20. Offergeld R, Ritter S, Faensen D, et al.: Infection epidemiological data among blood donors in Germany 2003-2004. Report of the Robert Koch Institute in accordance with article 22 of the transfusion act. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2005; 48:1273–1287
21. Offergeld R, Ritter S, Hamouda O: HIV, HCV, HBV and syphilis infections among blood donors in Germany 2005. Report from the Robert Koch Institute in accordance with article 22 of the transfusion act. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007; 50:1221–1231
22. Offergeld R, Ritter S, Hamouda O: HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012; 55:907–913
23. Willand L, Ritter S, Reinhard B, et al.: HIV, HCV, HBV and syphilis infections among blood donors in Germany 2006. Report from the Robert Koch Institute in accordance with article 22 of the transfusion act. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2008; 51:902–914
24. Robert-Koch-Institut: Publikationen und Berichte des Robert Koch-Instituts zur Blutspendersurveillance in Deutschland, German Transfusion Act §22 [Online: http://www.rki.de/DE/Content/Infekt/Blut/Transfusionsmedizin/Publikation/publikationen_node.html] (accessed 21 June 2016).
25. Peden A, McCardle L, Head MW, et al.: Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16:296–304
26. Busch MP, Young MJ, Samson SM, et al.: Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The transfusion safety study group. Transfusion 1991; 31:4–11
27. Yuan S, Ziman A, Smeltzer B, et al.: Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion 2010; 50:478–486
28. Eder AF, Dy BA, Kennedy JM, et al.: The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809–1819
29. Villanueva C, Colomo A, Bosch A, et al.: Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11–21
30. Zou S, Musavi F, Notari EP, et al.: Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. Transfusion 2010; 50:1487–1494
31. Guo N, Wang J, Ness P, et al.: Demographics of apheresis platelet donors in five blood centers in China. Transfusion 2012; 52:560–566
32. Pitman JP, Basavaraju SV, Shiraishi RW, et al.: Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections. Transfusion 2015; 55:1685–1692
33. Bundesgerichtshof; (VI ZR 279/04). Entscheidung vom 14.03.2006
34. Schrezenmeier H, Seifried E: Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99:1–15
35. Weisbach V, Koch HM, Angerer J, et al.: Di(2-ethylhexyl)phthalate exposure of apheresis donors is procedure-related. Transfusion 2006; 46:1457–1458; author reply 9